Background To evaluate the efficacy of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients not responding to conventional immune therapies. Methods An open-label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results